(NASDAQ)
.88
-0.0195   (-2.16%)
After Hours: .90 +0.0155 (+1.75%)
Volume (24h) Market Cap. Day Range 52w Range
5.99M 124.08M 0.80 - 0.92 0 - 2.34
Feb-22-21 09:00AM Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19GlobeNewswire
Feb-17-21 12:00PM Adamis Pharma Shares Fall Despite US Patent Covering NaloxoneBenzinga
09:00AM Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product CandidateGlobeNewswire
Feb-02-21 04:05AM Adamis Pharmaceuticals Announces Closing of Public Offering of Common StockGlobeNewswire
Jan-29-21 09:00AM Adamis Pharmaceuticals Announces Pricing of Public Offering of Common StockGlobeNewswire
Jan-28-21 04:01AM Adamis Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswire
09:00AM Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 PatientsGlobeNewswire
Jan-26-21 09:00AM Adamis Pharmaceuticals Provides Update On Its US Compounding BusinessGlobeNewswire
Jan-22-21 10:47AM FLDM Stock Alert: Why Fluidigm Shares Are Shooting Higher TodayInvestorPlace
09:59AM ADMP Stock: 4 Things to Know About Adamis Pharma Today as Shares Rocket AgainInvestorPlace
Jan-21-21 06:39AM Adamis’ COVID-19 Treatment Has Potential, but the Stock Is Still Not a Buy: AnalystTipRanks
04:05AM SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine ProductsGlobeNewswire
Jan-21-21 01:27AM Adamis (ADMP) Submits Tempol IND for COVID-19, Shares SoarZacks
10:02AM Looking Into Adamis Pharmaceuticals's Return On Capital EmployedBenzinga
Jan-21-21 08:05AM The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes ShoppingBenzinga
Jan-20-21 01:06AM Adamis Soars After Submitting Covid Drug to FDATheStreet.com
09:00AM Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19GlobeNewswire
Jan-08-21 08:30AM Adamis Pharmaceuticals (ADMP) Surges: Stock Moves 6.7% HigherZacks
Dec-01-20 09:00AM Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response LetterGlobeNewswire
Nov-18-20 12:24PM Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKSZacks
Nov-16-20 11:55AM Why Adamis Pharmaceuticals Stock Is Trading Lower TodayBenzinga
06:45AM Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHIGlobeNewswire
Nov-09-20 06:35AM Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Misses Revenue EstimatesZacks
05:11AM Adamis Pharmaceuticals: Q3 Earnings InsightsBenzinga
Nov-09-20 04:30AM Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business UpdateGlobeNewswire
03:15AM Adamis Pharmaceuticals Corp. to Host Earnings CallACCESSWIRE
Nov-05-20 09:00AM Adamis Pharmaceuticals Schedules Third Quarter 2020 Results Conference Call and Business UpdateGlobeNewswire
Nov-03-20 12:30PM Will Adamis Pharmaceuticals (ADMP) Report Negative Q3 Earnings? What You Should KnowZacks
Oct-12-20 10:24AM Looking Into Adamis Pharmaceuticals's Return On Capital EmployedBenzinga
Sep-18-20 09:00AM Adamis Pharmaceuticals Announces Pricing of Public Offering of Common StockGlobeNewswire
Sep-17-20 04:05AM Adamis Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswire
Sep-16-20 09:23AM New Strong Sell Stocks for September 16thZacks
Sep-03-20 04:05AM Adamis Pharmaceuticals Provides Update on Annual Meeting of StockholdersGlobeNewswire
Aug-25-20 09:00AM Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and ProposalsGlobeNewswire
Aug-17-20 05:55AM Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue EstimatesZacks
04:40AM Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business UpdateGlobeNewswire
Aug-14-20 09:00AM Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19GlobeNewswire
Aug-06-20 12:30PM Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks
Aug-05-20 04:05AM Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price RequirementGlobeNewswire
Jul-23-20 09:00AM Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?Zacks
Jul-01-20 09:00AM Adamis Pharmaceuticals Provides Update on SYMJEPI ProductsGlobeNewswire
Jun-18-20 09:00AM Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdoseGlobeNewswire
Jun-15-20 09:00AM Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19GlobeNewswire
May-27-20 09:00AM Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxoneGlobeNewswire
May-25-20 10:37AM Edited Transcript of ADMP earnings conference call or presentation 18-May-20 9:00pm GMTThomson Reuters StreetEvents
May-18-20 04:35AM Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business UpdateGlobeNewswire
09:00AM Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDAGlobeNewswire
May-15-20 09:00AM Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business UpdateGlobeNewswire
May-11-20 08:35AM Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI ProductsGlobeNewswire
Apr-29-20 12:00PM Adamis (ADMP) Moves to Strong Buy: Rationale Behind the UpgradeZacks
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Cap:    |  Volume (24h):